Galapagos与雅培达成13.5亿美元的II期JAK抑制剂交易

Pharmadeals Review Pub Date : 2012-06-03 DOI:10.3833/PDR.V2012I3.1693

Heather Cartwright

{"title":"Galapagos与雅培达成13.5亿美元的II期JAK抑制剂交易","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1693","DOIUrl":null,"url":null,"abstract":"Abbott has gained rights to Galapagos’ rheumatoid arthritis (RA) drug candidate GLPG0634 as part of a collaboration worth as much as US$1.35 B. Galapagos will receive US$150 M upfront and US$200 M upon successful completion of Phase II trials for RA, at which point Abbott will license the drug and assume sole responsibility for clinical development and global manufacturing. The deal ranks as the largest to date for a single Phase II asset and provides Abbott with a potential oral successor to Humira® (adalimumab).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"37 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I3.1693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abbott has gained rights to Galapagos’ rheumatoid arthritis (RA) drug candidate GLPG0634 as part of a collaboration worth as much as US$1.35 B. Galapagos will receive US$150 M upfront and US$200 M upon successful completion of Phase II trials for RA, at which point Abbott will license the drug and assume sole responsibility for clinical development and global manufacturing. The deal ranks as the largest to date for a single Phase II asset and provides Abbott with a potential oral successor to Humira® (adalimumab).\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"37 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I3.1693\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I3.1693","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

雅培获得了Galapagos的类风湿关节炎(RA)候选药物GLPG0634的权利，作为价值高达135 b美元的合作的一部分，Galapagos将获得1.5亿美元的预付款，并在RA的II期试验成功完成后获得2亿美元，届时雅培将获得该药物的许可，并承担临床开发和全球生产的唯一责任。该交易是迄今为止最大的单一II期资产，并为雅培提供了Humira®(阿达木单抗)的潜在口服继任者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor

Abbott has gained rights to Galapagos’ rheumatoid arthritis (RA) drug candidate GLPG0634 as part of a collaboration worth as much as US$1.35 B. Galapagos will receive US$150 M upfront and US$200 M upon successful completion of Phase II trials for RA, at which point Abbott will license the drug and assume sole responsibility for clinical development and global manufacturing. The deal ranks as the largest to date for a single Phase II asset and provides Abbott with a potential oral successor to Humira® (adalimumab).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量